No title
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce cardiovascular risk in obese individuals with established cardiovascular disease (CVD), potentially through modulating key risk factors. However, their benefit in primary prevention remains unclear. Objectives: This study aims to emulate GLP-1RA use for primary prevention by applying risk factor changes observed in the SELECT
